AKBA
Akebia Therapeutics, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Last price
0.91
▼ 0.01 (0.87%)
MARKET · —
Price
Open
0.92
Prev close
0.92
Day high
0.96
Day low
0.91
Volume
6.45M
Market cap
$251.22M
P/E (TTM)
—
52W range
0.81 – 3.22
Trailing performance
Returnvs SPY
1W
+3.89%
+5.3%
1M
-25.66%
-29.4%
3M
-11.08%
-14.2%
6M
-23.14%
-34.2%
YTD
-43.66%
-56.0%
1Y
-70.93%
-90.9%
3Y
-28.02%
-102.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$251.22M
Enterprise value$294.86M
Revenue (TTM)$219.06M
Gross profit$178.37M
EBITDA$-4.32M
Net income$-29.67M
EPS (TTM)$-0.12
Free cash flow$33.62M
Total cash$155.55M
Total debt$199.19M
Book value / share$0.09
Shares outstanding277.11M
Float270.60M
Short % of float7.02%
Dividend yield—
Beta (5Y)0.24
Valuation & profitability ratios
Trailing P/E—
Forward P/E-2.75
PEG ratio—
Price / sales—
Price / book9.85
EV / revenue1.35
EV / EBITDA-68.19
Gross margin81.43%
Operating margin-5.46%
Profit margin-13.54%
Return on equity-109.38%
Return on assets-1.06%
Debt / equity796.18
Current ratio1.43
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $236.20M | $160.18M | $194.62M | $292.60M |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$5.34M | -$69.41M | -$51.92M | -$92.56M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$5.34M | -$69.41M | -$51.92M | -$92.56M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.03 | -0.03 | -3.2% |
| Mar 2026 | -0.02 | -0.03 | -50.0% |
| Dec 2025 | -0.06 | -0.05 | +16.7% |
| Sep 2025 | -0.01 | 0.00 | +100.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.04 | 1 | $46.55M | -20.8% |
| Next quarter | -0.05 | 1 | $47.56M | -17.5% |
| Current year | -0.16 | 1 | $196.84M | -16.7% |
| Next year | -0.33 | 1 | $140.04M | -28.9% |
Analyst targets & ownership
Mean target$3.80
High target$6.00
Low target$1.00
Implied upside316.94%
Analyst count5
ConsensusBUY
Strong buy / Buy1 / 3
Hold1
Sell / Strong sell0 / 0
Held by insiders4.06%
Held by institutions43.03%
Institutions holding226
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
+577.45K
Net buying
Buy transactions
8
633.47K shares
Sell transactions
1
56.02K shares
Net transactions
+9
Buys less sells
Sell : buy shares
0.1 : 1
Mixed
Insider-held shares
11.24M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 6, 26 | BUTLER JOHN P Chief Executive Officer |
CONVERSION | 350.00K | $220.50K | Direct |
| Jun 29, 26 | OSTROWSKI ERIK Chief Financial Officer |
SELL | 56.02K | $62.18K | Direct |
| Jun 17, 26 | ZUMWALT LEANNE M Director |
STOCK | 35.70K | $0 | Direct |
| Jun 17, 26 | SMITH CYNTHIA Director |
STOCK | 35.70K | $0 | Direct |
| Jun 17, 26 | ROGERS MICHAEL W Director |
STOCK | 35.70K | $0 | Direct |
| Jun 17, 26 | ADAMS ADRIAN Director |
STOCK | 35.70K | $0 | Direct |
| Jun 17, 26 | WOLF MYLES Director |
STOCK | 35.70K | $0 | Direct |
| Jun 17, 26 | FRIESON RON Director |
STOCK | 35.70K | $0 | Direct |
| Mar 4, 26 | BUTLER JOHN P Chief Executive Officer |
BUY | 69.27K | $86.59K | Direct |
| Feb 2, 26 | BURKE STEVEN KEITH Officer |
SELL | 67.66K | $94.05K | Direct |
| Feb 2, 26 | BUTLER JOHN P Chief Executive Officer |
SELL | 341.31K | $474.41K | Direct |
| Feb 2, 26 | GRUND NICHOLAS Officer |
SELL | 84.83K | $117.91K | Direct |
| Feb 2, 26 | OSTROWSKI ERIK Chairman of the Board |
SELL | 34.95K | $48.58K | Direct |
| Feb 2, 26 | MALABRE RICHARD C. Officer |
SELL | 49.52K | $68.84K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ADAMS ADRIAN |
Director | 236.20K | Stock Award(Grant) |
BURKE STEVEN KEITH |
Officer | 948.43K | Sale |
BUTLER JOHN P |
Chief Executive Officer | 3.88M | Conversion of Exercise of derivative security |
GRUND NICHOLAS |
Officer | 561.75K | Sale |
MALABRE RICHARD C. |
Officer | 299.39K | Sale |
OSTROWSKI ERIK |
Chief Financial Officer | 616.62K | Sale |
ROGERS MICHAEL W |
Director | 197.43K | Stock Award(Grant) |
RUCCI CAROLYN M |
Officer | 588.38K | Sale |
SMITH CYNTHIA |
Director | 196.63K | Stock Award(Grant) |
WOLF MYLES |
Director | 169.08K | Stock Award(Grant) |
Moving averages & technicals
SMA 10
0.88
+3.92% from price
SMA 20
1.05
-13.76% from price
SMA 50
1.14
-20.57% from price
SMA 100
1.19
-23.26% from price
SMA 200
1.34
-32.35% from price
EMA 12
0.94
-3.30% from price
EMA 26
1.04
-12.29% from price
EMA 50
1.11
-17.58% from price
RSI (14)
35.9
Neutral
MACD (12,26,9)
-0.10
Hist -0.01
ATR (14)
0.08
9.09% of price
Realised vol 30D
97.7%
Annualised
Bollinger upper
1.46
20, 2σ
Bollinger lower
0.64
20, 2σ
50 / 200 cross
Death
1.14 vs 1.34
Trend bias
Below 200
-32.35%
Risk profile
Beta vs SPY
1.13
More volatile than market
Correlation to SPY
0.19
Largely independent
Realised vol 30D
97.7%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-73.5%
Peak to trough
Max drawdown 5Y
-92.5%
Peak to trough
ATR 14
0.08
9.09% of price
Beta (reported)
0.24
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
0.00
Call-heavy session
Put / call open interest
0.03
Positioning, not flow
Max pain
1.00
+10.3% from spot
ATM implied vol
110.9%
Nearest strike to spot
Skew (10% OTM)
-20.3%
Calls bid over puts
Call volume
64
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
1.50
126 contracts
Heaviest put OI
1.00
3 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Akebia Therapeutics Inc (AKBA) (Q2 2026) Earnings Call Highlights: Vafseo Surges 60% as VOICE ...
GuruFocus.com · 17d ago
Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates
Zacks · 17d ago
Akebia Therapeutics Q2 Earnings Call Highlights
MarketBeat · 17d ago
Akebia Therapeutics: Q2 Earnings Snapshot
Associated Press · 17d ago
Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
GlobeNewswire · 17d ago
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 19d ago
Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases
GlobeNewswire · 19d ago
Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights
GlobeNewswire · 24d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.